Muscarinic acetylcholine receptor (M3)
Assets acting on this target.
- Class
- Muscarinic M3 receptor antagonist (anticholinergic bronchodilator)
- Pathway
- blocks acetylcholine-mediated airway smooth-muscle contraction
The M3 muscarinic acetylcholine receptor is a G-protein-coupled receptor expressed on airway smooth muscle, submucosal glands, and other tissues. In the lungs, the neurotransmitter acetylcholine, released from vagal nerve endings, binds M3 receptors to trigger smooth-muscle contraction and mucus secretion. This cholinergic tone is a major contributor to airway narrowing in chronic obstructive pulmonary disease (COPD) and, to a lesser degree, asthma. Blocking M3 with an antagonist ('anticholinergic' or antimuscarinic agent) prevents acetylcholine from activating this contractile pathway, producing bronchodilation and reduced mucus output. Because acetylcholine also acts on a related subtype, M2, which normally provides negative feedback on its own release, effective bronchodilators are designed to act preferentially at M3 over M2 so as not to blunt this self-limiting mechanism. Antimuscarinic bronchodilators fall into short-acting and long-acting classes, distinguished largely by how quickly the drug dissociates from the receptor once bound; short-acting agents wash out relatively quickly, while long-acting ones remain bound for many hours, allowing once- or twice-daily dosing. This mechanism broadly matters wherever cholinergic-driven bronchoconstriction is a dominant feature of airway disease, and it complements other bronchodilator classes such as beta-agonists, which act through a distinct signaling pathway.
By indication
Related mechanisms
Muscarinic acetylcholine receptor (M3) drugs compared
11 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Aclidinium bromideTudorza Pressair | Azurity Pharmaceuticals | small molecule | Approved | Approved in Chronic Obstructive Pulmonary Disease |
| Aclidinium bromide/formoterol fumarateDuaklir Pressair | Almirall, Azurity Pharmaceuticals | small molecule combination | Approved | Approved in Chronic Obstructive Pulmonary Disease |
| fluticasone furoate/umeclidinium/vilanterolTrelegy Ellipta | GlaxoSmithKline | small molecule combination | Approved | Approved in Asthma; Approved in Chronic Obstructive Pulmonary Disease |
| Glycopyrrolate/formoterol fumarateBevespi Aerosphere | AstraZeneca | small molecule combination | Approved | Approved in Chronic Obstructive Pulmonary Disease |
| Ipratropium | Boehringer Ingelheim | small molecule | Approved | Approved in Chronic Obstructive Pulmonary Disease; Phase 3 in Asthma |
| Olodaterol/tiotropium bromide | Boehringer Ingelheim | small molecule combination | Approved | Approved in Chronic Obstructive Pulmonary Disease |
| Tiotropium bromide | Boehringer Ingelheim | small molecule | Approved | Approved in Asthma; Approved in Chronic Obstructive Pulmonary Disease |
| UmeclidiniumIncruse Ellipta | GlaxoSmithKline | small molecule | Approved | Approved in Chronic Obstructive Pulmonary Disease; Phase 2 in Asthma |
| Umeclidinium/Vilanterol | GlaxoSmithKline, Innoviva, Sino Biopharmaceutical | small molecule combination | Approved | Approved in Chronic Obstructive Pulmonary Disease |
| Oxitropium bromide (Ba253BINEB) | Boehringer Ingelheim | small molecule | Phase 3 | Phase 3 in Asthma |
| Glycopyrronium (PT001) | AstraZeneca | small molecule | Phase 2/3 | Phase 2/3 in Asthma |